MedPath

Effects of a Home-Based Exercise Intervention in Subjects with Long COVID

Not Applicable
Active, not recruiting
Conditions
Post-COVID-19 Syndrome
Long COVID-19
Interventions
Other: home-based concurrent exercise
Registration Number
NCT06073002
Lead Sponsor
University of Vienna
Brief Summary

The current Coronavirus Disease 2019 (COVID-19) pandemic is the most severe health crisis of the 21st century. This is not only due to the deaths caused by the disease. People that were affected by COVID-19 and supposedly recovered may suffer from long lasting sequelae. The presence of symptoms longer than 3 months after the infection with the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is referred to as Post-COVID-19 Syndrome or Long COVID-19. It is estimated that 10-20 percent of all infected people are affected. The most common symptoms include persistent fatigue, reduced physical capacity, dyspnoea, ageusia, anosmia, musculoskeletal pain and neuropsychological complaints such as depression, anxiety, insomnia and a loss of concentration.

Considering the novelty of the pathology, evidence on the successful treatment of Post-COVID/Long-COVID is scarce. Physical activity has been established as a treatment option for chronic diseases that have similar symptomatic manifestations to those of Post-COVID/Long-COVID. For example, exercise therapy has shown positive effects on the health status of patients with lung disease, depression, anxiety, insomnia and cognitive impairment. However, there has been controversy whether so-called Graded Exercise Therapy (GET) is a safe treatment strategy for patients with Chronic Fatigue Syndrome (CFS). This population may experience Post Exertional Malaise (PEM), a worsening of symptoms after physical, cognitive or emotional exertion. Since COVID-19 might be an infectious trigger for CFS, particular caution has to be taken when recruiting participants and when screening them for adverse events and worsening of symptoms during an exercise intervention.

It can be hypothesized that patients suffering from Post-COVID/Long-COVID can benefit from exercise in various ways, guaranteed that there is sufficient screening for PEM before and during the intervention and training volume and intensity are increased slowly and progressively.

The current study investigates the effects of a home-based concurrent training program on various parameters in people affected by Long COVID.

Detailed Description

Not available

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
20
Inclusion Criteria
  • laboratory-confirmed infection with SARS-CoV-2 via PCR a minimum of 12 weeks ago
  • presence of at least one or more of persistent symptoms that can be attributed to Long-COVID
Exclusion Criteria
  • previous or current hospitalization due to the COVID-19 disease
  • regular engagement in endurance or strength training (more than once per week) in the six months prior to enrollment
  • contraindications for physical endurance and resistance exercise according to the guidelines of the American College of Sports Medicine (ACSM)
  • a grade of 3 or higher on the Post-COVID-19 Functional Status Scale (PCFS)
  • presence of post exertional malaise (PEM)

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Home-based concurrent traininghome-based concurrent exerciseCombination of resistance training (5 exercises with bodyweight and/or resistance bands; 3 sets per exercise, 15-20 repetitions) and endurance training (mode of choice, light to moderate intensities which are monitored via heartrate zones, 20-40min per sessions); 3 weekly sessions on non-consecutive days
Primary Outcome Measures
NameTimeMethod
Change of peak oxygen consumption (VO2peak measured in ml/min/kg)at baseline and at 12 weeks

VO2peak will be assessed during cardio pulmonary exercise testing (CPET) on a bicycle ergometer.

Secondary Outcome Measures
NameTimeMethod
Change of Standard Deviation of RR-Intervals (SDNN measured in ms)at baseline and at 12 weeks

SDNN will be assessed via a short-term heart rate variability (HRV) measurement (BioSign).

Change of maximum lower body isometric muscle strength (measured in N)at baseline and at 12 weeks

Maximum lower body isometric muscle strength will be assessed via a leg press with integrated isometric force measurement (Compass 530, Suessmed GmbH).

Change of the number of present Long-COVID specific symptomsat baseline and at 12 weeks

The number of Long-COVID specific symptoms will be assessed using a list of symptoms provided by the National Institute for Health Care and Excellence (NICE). Each item will be referenced to as existent (yes) or non-existent (no) during the last 7 days.

Change of fatigue assessed via the Fatigue Severity Scale (FSS)at baseline and at 12 weeks

The FSS is a 9-item self-report questionnaire using a 1-7 Likert-scale

Change of dyspnoea assessed via the modified Medical Research Council (mMRC) dyspnoea scaleat baseline and at 12 weeks

The mMRC dyspnoea scale measures perceived breathlessness and classifies subjects into dyspnoea grades from 0-4.

Change of Root Mean Square of Successive Differences (RMSSD measured in ms)at baseline and at 12 weeks

RMSSD will be assessed via a short-term heart rate variability (HRV) measurement (BioSign).

Change of health-related quality of life (HQoL) assessed via the SF-36 1.0at baseline an at 12 weeks

The SF-36 1.0 is self-administered questionnaire and will be scored according to RAND (numeric value of 0-100). A high score represents a more favorable health status.

Change of maximum hand grip strength (measured in kg)at baseline and at 12 weeks

Maximum hand grip strength will be assessed via a hand grip dynamometer (Saehan SH5001).

Change of interleukin-6 (IL-6 measured in pg/ml)at baseline and at 12 weeks

IL-6 will be assessed via blood sample.

Change of tumor necrosis factor alpha (TNF-α measured in pg/ml)at baseline and at 12 weeks

TNF-α will be assessed via blood sample.

Change of mean time "correct rejection" (CR, speed during concentrated working measured in s)at baseline and at 12 weeks

CR will be assessed via Cognitrone (Schuhfried GmbH), which is a carefully administered computer test. Participants will be given the task of comparing a series of geometric figures.

Trial Locations

Locations (1)

Department of Sport and Human Movement Science

🇦🇹

Vienna, Austria

© Copyright 2025. All Rights Reserved by MedPath